Phase 3 study for people with Motor Neurone Disease

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 13 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Mario Negri Institute for Pharmacological Research
Registry number NCT06126315
Started 26 March 2025 Today 16 October 2026 Estimated completion 1 April 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Concord Hospital Sydney NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 13 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 246

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Age 18+;

2. ALS diagnosis according to the Gold Coast Criteria;

3. Disease duration \< 24 months from symptom onset, as indicated by limb weakness or bulbar symptoms, at the randomization/baseline visit\*;

4. Self-sufficiency \[Satisfactory bulbar and spinal function (score 3+ on the ALSFRS-R for swallowing, cutting food and handling utensils, and walking)\];

5. Satisfactory respiratory function (FVC ≥80% of predicted);

6. Documented progression of symptoms as measured by the ALSFRS-R scale. Disease progression rate (DFS) must be\>= 0.33. DFS =(48- ALSFRS-R at screening)/months from onset to screening.

7. Ability to understand and comply with the study requirements;

8. Ability to give written informed consent personally or, as an alternative, via a legally authorized representative;

9. Treatment with riluzole 50 mg twice/day for at least 4 weeks prior to randomization visit;

10. Intact cognitive function, again determined by the Principal Investigator.

* The qualifying first symptoms of ALS are limited to manifestations of weakness in extremity, bulbar, or respiratory muscles. Cramps, fasciculations, or fatigue should not be taken in isolation as a first symptom of ALS.

Exclusion Criteria:

1. Antecedent polio infection or other active infection;

2. Motor neuron disease (MND) other than ALS;

3. Involvement of other systems possibly determining a functional impairment (as measured by the endpoints) for the entire duration of the study;

4. Other severe clinical conditions (e.g., cardiovascular disorders, neoplasms) with an impact on survival or functional disability in the next 12 months;

5. Previous use of ALCAR for any reason;

6. Poor compliance with previous treatments;

7. Other experimental treatments in the three months prior to the screening visit (if a subject is receiving another experimental drug, a 3-month wash-out period before participating in the present clinical trial will be required);

8. Women who are lactating or able to become pregnant (e.g. who are not post-menopausal, surgically sterile, or using inadequate birth control) and men unable to practice contraception for the duration of the treatment and three months after its completion;

9. Inability to understand and comply with the study requirements;

10. Unwillingness or inability to take riluzole.

Dates on the record

Started 26 March 2025
Estimated completion 1 April 2027
Registry last updated 6 October 2026
Checked by Voxsanity 13 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 6 October 2026.
  • This page last checked by Voxsanity: 13 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.